Cosponsor H.R. 2905, the Medicare IVIG Access Enhancement Act

We are writing to urge you to cosponsor our bipartisan legislation, H.R. 2905, the Medicare IVIG Access Enhancement Act. The bill would provide much-needed assistance to Medicare patients suffering from two rare diseases, Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN). These debilitating conditions are the result of a patient’s own immune system attacking their motor nerves, leading to compromised mobility and reduced quality of life. Patients are frequently treated
with intravenous immune globulin (IVIG), a plasma-derived medicine that can significantly improve health outcomes for these vulnerable patient populations.

Read More

Cosponsor H.R. 2905, the Medicare IVIG Access Enhancement Act

We are writing to urge you to cosponsor our bipartisan legislation, H.R. 2905, the Medicare IVIG Access Enhancement Act. The bill would provide much-needed assistance to Medicare patients suffering from two rare diseases, Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN). These debilitating conditions are the result of a patient’s own immune system attacking their motor nerves, leading to compromised mobility and reduced quality of life. Patients are frequently treated
with intravenous immune globulin (IVIG), a plasma-derived medicine that can significantly improve health outcomes for these vulnerable patient populations.

Read More

Cosponsor H.R. 2905, the Medicare IVIG Access Enhancement Act

We are writing to urge you to cosponsor our bipartisan legislation, H.R. 2905, the Medicare IVIG Access Enhancement Act. The bill would provide much-needed assistance to Medicare patients suffering from two rare diseases, Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN). These debilitating conditions are the result of a patient’s own immune system attacking their motor nerves, leading to compromised mobility and reduced quality of life. Patients are frequently treated
with intravenous immune globulin (IVIG), a plasma-derived medicine that can significantly improve health outcomes for these vulnerable patient populations.

Read More

Cosponsor H.R. 2905, the Medicare IVIG Access Enhancement Act

We are writing to urge you to cosponsor our bipartisan legislation, H.R. 2905, the Medicare IVIG Access Enhancement Act. The bill would provide much-needed assistance to Medicare patients suffering from two rare diseases, Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN). These debilitating conditions are the result of a patient’s own immune system attacking their motor nerves, leading to compromised mobility and reduced quality of life. Patients are frequently treated
with intravenous immune globulin (IVIG), a plasma-derived medicine that can significantly improve health outcomes for these vulnerable patient populations.

Read More

COSPONSOR: H.R. 2705, the Water Infrastructure Trust Fund Act of 2019

Please join me as a cosponsor of H.R. 2705, the Water Infrastructure Trust Fund Act of 2019. H.R. 2705 provides a small, deficit-neutral source of revenue to help states replace, repair, and rehabilitate critical clean and drinking water
facilities. Half of the trust fund revenue will be distributed to local governments as grants and loans through the Clean Water State Revolving Fund (CWSRF) for wastewater treatment construction, while the other half will be distributed through the Drinking
Water State Revolving Fund (DWSRF) to finance projects to meet federal drinking water standards. The Water Infrastructure Trust Fund will be capitalized by a voluntary labeling and fee system, to which businesses that rely on a clean water source can opt-in.
Participating businesses would include a small label on their products indicating their commitment to protecting America’s clean water, contributing $0.03 to the trust fund per labelled unit. Businesses and products that could take advantage of the labeling
system include: water-based beverages, products disposed of in wastewater, and pharmaceuticals.

Read More